2019 | Page 3 of 20 | Certara

Quantitative Systems Toxicology Approach Integrates Simcyp PBPK and Core Hepatocyte Metabolism: a Case Study with Valproic Acid

October 16, 2019

Certara Celebrates 20th Anniversary of the Simcyp Simulator Consortium

October 16, 2019

Oct 16, 2019 The most influential scientific research consortium of its kind: 37 biopharmaceutical companies work in a pre-competitive environment to advance PBPK modeling and simulation, progress new drug and biologics research, create new regulatory frontiers, foster ongoing modeling and simulation education, and present industry awards

Prediction of mAb disposition in hepatic impairment – Evolocumab as a case study

October 15, 2019

Use of a physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model to guide dose adjustments to S-warfarin in different populations

October 15, 2019

Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed PBPK Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions

October 15, 2019

Accounting for CYP2C19 mechanism based inhibition and CYP1A2 induction in a PBPK model for omeprazole

October 11, 2019

Physiological verification of a geriatric population using the Simcyp R package

October 11, 2019

Estimation of Effective pKa of Bicarbonate Buffer

October 11, 2019

Quantification of Human Blood-Brain Barrier Transporters in Health and in Dementia by Global and Targeted Proteomics

October 11, 2019

The Molecular Stethoscope: RNA of Drug Metabolising Enzymes in Circulating Vesicles Correlates with their Specific Protein Content in the Liver

October 11, 2019

3 of 20